Share Price and Basic Stock Data
Last Updated: January 7, 2026, 9:02 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Gujarat Terce Laboratories Ltd operates in the pharmaceuticals industry, with its stock priced at ₹47.9 and a market capitalization of ₹35.5 Cr. The company has demonstrated fluctuating sales performance over the past few quarters. Sales stood at ₹9.41 Cr in June 2022, rising to ₹12.58 Cr by September 2022, before peaking at ₹13.02 Cr in December 2023. However, recent quarters have shown some volatility, with a decline to ₹10.72 Cr in June 2023, followed by a recovery to ₹12.03 Cr in September 2023. For the trailing twelve months (TTM) ending March 2025, sales are reported at ₹48.78 Cr. Despite this growth, the operating profit margin (OPM) remains negative at -0.09%, indicating persistent challenges in cost management. The company’s revenue from operations per share increased to ₹67.64, reflecting its efforts to enhance sales efficiency. Overall, Gujarat Terce Laboratories is navigating a competitive landscape with mixed results in sales growth and profitability.
Profitability and Efficiency Metrics
The profitability of Gujarat Terce Laboratories has been under pressure, with a reported net profit of -₹1.02 Cr for the TTM ending March 2025. This follows a decline from a net profit of ₹0.32 Cr in March 2024, highlighting ongoing operational challenges. The company’s return on equity (ROE) stood at 14.6%, while the return on capital employed (ROCE) was significantly higher at 41.4%, indicating effective capital utilization despite the net loss. The interest coverage ratio (ICR) of 10.09x suggests that the company is well-positioned to meet its interest obligations. However, the operating profit margin has remained erratic, with a negative OPM of -1.94% for the year ending March 2025. Additionally, the cash conversion cycle of 38.02 days reflects a reasonable efficiency in managing working capital, although the company still faces challenges in translating sales into profit.
Balance Sheet Strength and Financial Ratios
Gujarat Terce Laboratories maintains a relatively stable balance sheet, with total borrowings reported at ₹0.60 Cr against reserves of ₹0.42 Cr. The debt-to-equity ratio stands at 0.14, indicating low leverage, which is favorable for financial stability. The company’s current ratio is slightly below 1 at 0.95, suggesting potential liquidity concerns. The price-to-book value ratio is high at 7.00x, indicating that the stock is trading at a premium compared to its book value of ₹8.73 per share. This could reflect market expectations for future growth, despite recent financial struggles. The asset turnover ratio of 2.18% indicates effective use of assets to generate revenue, which is relatively high compared to industry standards. However, the declining reserves and the negative net profit margin of -1.94% signal caution for potential investors regarding the company’s ability to sustain operations without increased profitability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Gujarat Terce Laboratories illustrates a predominantly public ownership structure, with public shareholders holding 62.97% of the shares as of March 2025. Promoters hold a stable 37.03%, reflecting a consistent commitment to the company. The number of shareholders has increased slightly to 13,812, indicating growing interest in the stock despite recent performance challenges. The absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) suggests limited institutional confidence, which might influence stock liquidity and price stability. The promoter holding has steadily increased from 36.22% in December 2022, which could be interpreted as a sign of confidence from company insiders. However, the lack of institutional backing may pose a risk for retail investors, as institutional investors often provide stability and credibility to the stock.
Outlook, Risks, and Final Insight
Gujarat Terce Laboratories faces a mixed outlook, characterized by both potential growth opportunities and significant risks. The company’s high ROCE of 41.4% suggests that it can generate substantial returns on its capital investments, which may bode well for future profitability if operational efficiencies improve. However, the persistent negative net profit, coupled with declining reserves, raises concerns about the sustainability of its operations. The volatility in sales and the negative OPM indicate that management must address cost structures and operational efficiency. Risks include reliance on a public shareholder base without institutional support and the potential impacts of market competition in the pharmaceutical sector. Overall, while there are opportunities for recovery and growth, particularly if the company can stabilize its operational performance, investors should remain cautious about the inherent risks associated with its current financial state and market positioning.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 100 | 214/84.3 | 27.9 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,631 Cr. | 424 | 479/192 | 95.9 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.5 Cr. | 46.5 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.1 Cr. | 39.7 | 40.0/17.0 | 138 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,857.92 Cr | 1,159.04 | 54.40 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12.58 | 11.90 | 12.89 | 10.72 | 12.03 | 13.02 | 12.21 | 11.89 | 13.30 | 12.68 | 12.32 | 10.85 | 12.93 |
| Expenses | 12.98 | 11.77 | 13.08 | 11.85 | 11.48 | 12.18 | 11.20 | 11.81 | 11.64 | 11.60 | 11.27 | 10.86 | 11.04 |
| Operating Profit | -0.40 | 0.13 | -0.19 | -1.13 | 0.55 | 0.84 | 1.01 | 0.08 | 1.66 | 1.08 | 1.05 | -0.01 | 1.89 |
| OPM % | -3.18% | 1.09% | -1.47% | -10.54% | 4.57% | 6.45% | 8.27% | 0.67% | 12.48% | 8.52% | 8.52% | -0.09% | 14.62% |
| Other Income | 0.10 | 0.08 | 0.10 | 0.08 | 0.08 | 0.08 | 0.08 | 0.07 | 0.08 | 0.07 | 0.09 | 0.09 | 0.06 |
| Interest | 0.22 | 0.14 | 0.17 | 0.17 | 0.20 | 0.16 | 0.15 | 0.13 | 0.13 | 0.08 | 0.07 | 0.05 | 0.07 |
| Depreciation | 0.07 | 0.07 | 0.16 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.10 | 0.10 | 0.10 | 0.10 |
| Profit before tax | -0.59 | -0.00 | -0.42 | -1.31 | 0.34 | 0.67 | 0.85 | -0.07 | 1.52 | 0.97 | 0.97 | -0.07 | 1.78 |
| Tax % | -0.00% | -290.48% | -0.00% | -0.00% | -0.00% | 35.29% | 14.29% | 1.97% | -3.09% | 449.48% | -42.86% | 21.35% | |
| Net Profit | -0.59 | -0.00 | 0.80 | -1.31 | 0.33 | 0.67 | 0.54 | -0.08 | 1.48 | 1.01 | -3.39 | -0.04 | 1.40 |
| EPS in Rs | -0.80 | -0.00 | 1.08 | -1.77 | 0.44 | 0.90 | 0.73 | -0.11 | 1.99 | 1.36 | -4.57 | -0.05 | 1.89 |
Last Updated: January 8, 2026, 3:03 am
Below is a detailed analysis of the quarterly data for Gujarat Terce Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 12.93 Cr.. The value appears strong and on an upward trend. It has increased from 10.85 Cr. (Jun 2025) to 12.93 Cr., marking an increase of 2.08 Cr..
- For Expenses, as of Sep 2025, the value is 11.04 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 10.86 Cr. (Jun 2025) to 11.04 Cr., marking an increase of 0.18 Cr..
- For Operating Profit, as of Sep 2025, the value is 1.89 Cr.. The value appears strong and on an upward trend. It has increased from -0.01 Cr. (Jun 2025) to 1.89 Cr., marking an increase of 1.90 Cr..
- For OPM %, as of Sep 2025, the value is 14.62%. The value appears strong and on an upward trend. It has increased from -0.09% (Jun 2025) to 14.62%, marking an increase of 14.71%.
- For Other Income, as of Sep 2025, the value is 0.06 Cr.. The value appears to be declining and may need further review. It has decreased from 0.09 Cr. (Jun 2025) to 0.06 Cr., marking a decrease of 0.03 Cr..
- For Interest, as of Sep 2025, the value is 0.07 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.05 Cr. (Jun 2025) to 0.07 Cr., marking an increase of 0.02 Cr..
- For Depreciation, as of Sep 2025, the value is 0.10 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.10 Cr..
- For Profit before tax, as of Sep 2025, the value is 1.78 Cr.. The value appears strong and on an upward trend. It has increased from -0.07 Cr. (Jun 2025) to 1.78 Cr., marking an increase of 1.85 Cr..
- For Tax %, as of Sep 2025, the value is 21.35%. The value appears to be increasing, which may not be favorable. It has increased from -42.86% (Jun 2025) to 21.35%, marking an increase of 64.21%.
- For Net Profit, as of Sep 2025, the value is 1.40 Cr.. The value appears strong and on an upward trend. It has increased from -0.04 Cr. (Jun 2025) to 1.40 Cr., marking an increase of 1.44 Cr..
- For EPS in Rs, as of Sep 2025, the value is 1.89. The value appears strong and on an upward trend. It has increased from -0.05 (Jun 2025) to 1.89, marking an increase of 1.94.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:36 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 28.84 | 26.48 | 25.00 | 25.29 | 29.01 | 31.03 | 37.54 | 25.18 | 40.13 | 46.78 | 47.92 | 50.20 | 48.78 |
| Expenses | 27.89 | 25.70 | 24.84 | 25.21 | 28.68 | 30.54 | 36.86 | 27.77 | 39.02 | 48.94 | 46.65 | 46.31 | 44.77 |
| Operating Profit | 0.95 | 0.78 | 0.16 | 0.08 | 0.33 | 0.49 | 0.68 | -2.59 | 1.11 | -2.16 | 1.27 | 3.89 | 4.01 |
| OPM % | 3.29% | 2.95% | 0.64% | 0.32% | 1.14% | 1.58% | 1.81% | -10.29% | 2.77% | -4.62% | 2.65% | 7.75% | 8.22% |
| Other Income | 0.13 | 0.08 | 0.19 | 0.44 | 0.41 | 0.32 | 0.29 | 0.62 | 0.31 | 0.35 | 0.32 | 0.31 | 0.31 |
| Interest | 0.41 | 0.41 | 0.38 | 0.31 | 0.23 | 0.25 | 0.29 | 0.39 | 0.40 | 0.72 | 0.68 | 0.42 | 0.27 |
| Depreciation | 0.33 | 0.16 | 0.19 | 0.19 | 0.19 | 0.21 | 0.24 | 0.18 | 0.28 | 0.36 | 0.37 | 0.38 | 0.40 |
| Profit before tax | 0.34 | 0.29 | -0.22 | 0.02 | 0.32 | 0.35 | 0.44 | -2.54 | 0.74 | -2.89 | 0.54 | 3.40 | 3.65 |
| Tax % | 29.41% | 72.41% | 209.09% | 150.00% | 15.62% | -25.71% | 36.36% | -0.39% | -17.57% | -42.21% | 55.56% | 128.53% | |
| Net Profit | 0.24 | 0.09 | -0.67 | -0.01 | 0.27 | 0.43 | 0.28 | -2.52 | 0.87 | -1.67 | 0.24 | -0.98 | -1.02 |
| EPS in Rs | 0.32 | 0.12 | -0.90 | -0.01 | 0.36 | 0.58 | 0.38 | -3.40 | 1.17 | -2.25 | 0.32 | -1.32 | -1.37 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -62.50% | -844.44% | 98.51% | 2800.00% | 59.26% | -34.88% | -1000.00% | 134.52% | -291.95% | 114.37% | -508.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | -781.94% | 942.95% | 2701.49% | -2740.74% | -94.14% | -965.12% | 1134.52% | -426.48% | 406.33% | -622.70% |
Gujarat Terce Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
No data available for the compounded sales growth chart.
Balance Sheet
Last Updated: December 4, 2025, 3:00 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 |
| Reserves | 3.52 | 3.61 | 2.94 | 2.64 | 2.98 | 3.41 | 3.69 | 0.24 | 1.11 | -0.56 | -0.31 | -0.94 | 0.42 |
| Borrowings | 8.74 | 8.21 | 7.13 | 7.00 | 0.37 | 0.68 | 2.60 | 4.74 | 6.67 | 7.27 | 3.87 | 0.94 | 0.60 |
| Other Liabilities | 6.24 | 7.06 | 6.98 | 6.59 | 8.69 | 7.94 | 8.80 | 9.47 | 12.19 | 14.39 | 12.29 | 15.41 | 15.99 |
| Total Liabilities | 25.92 | 26.30 | 24.47 | 23.65 | 19.46 | 19.45 | 22.51 | 21.87 | 27.39 | 28.52 | 23.27 | 22.83 | 24.43 |
| Fixed Assets | 6.13 | 6.48 | 6.34 | 6.17 | 1.88 | 2.06 | 2.29 | 2.45 | 4.29 | 3.99 | 3.69 | 3.65 | 3.47 |
| CWIP | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.30 | 0.30 | 0.24 | 0.27 | 0.29 | 0.27 | 0.27 | 0.27 | 0.27 | 0.27 | 0.52 | 2.62 |
| Other Assets | 19.77 | 19.52 | 17.83 | 17.24 | 17.31 | 17.10 | 19.95 | 19.15 | 22.83 | 24.26 | 19.31 | 18.66 | 18.34 |
| Total Assets | 25.92 | 26.30 | 24.47 | 23.65 | 19.46 | 19.45 | 22.51 | 21.87 | 27.39 | 28.52 | 23.27 | 22.83 | 24.43 |
Below is a detailed analysis of the balance sheet data for Gujarat Terce Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 7.42 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 7.42 Cr..
- For Reserves, as of Sep 2025, the value is 0.42 Cr.. The value appears strong and on an upward trend. It has increased from -0.94 Cr. (Mar 2025) to 0.42 Cr., marking an increase of 1.36 Cr..
- For Borrowings, as of Sep 2025, the value is 0.60 Cr.. The value appears to be improving (decreasing). However, Borrowings exceed Reserves, which may signal higher financial risk. It has decreased from 0.94 Cr. (Mar 2025) to 0.60 Cr., marking a decrease of 0.34 Cr..
- For Other Liabilities, as of Sep 2025, the value is 15.99 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15.41 Cr. (Mar 2025) to 15.99 Cr., marking an increase of 0.58 Cr..
- For Total Liabilities, as of Sep 2025, the value is 24.43 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 22.83 Cr. (Mar 2025) to 24.43 Cr., marking an increase of 1.60 Cr..
- For Fixed Assets, as of Sep 2025, the value is 3.47 Cr.. The value appears to be declining and may need further review. It has decreased from 3.65 Cr. (Mar 2025) to 3.47 Cr., marking a decrease of 0.18 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 2.62 Cr.. The value appears strong and on an upward trend. It has increased from 0.52 Cr. (Mar 2025) to 2.62 Cr., marking an increase of 2.10 Cr..
- For Other Assets, as of Sep 2025, the value is 18.34 Cr.. The value appears to be declining and may need further review. It has decreased from 18.66 Cr. (Mar 2025) to 18.34 Cr., marking a decrease of 0.32 Cr..
- For Total Assets, as of Sep 2025, the value is 24.43 Cr.. The value appears strong and on an upward trend. It has increased from 22.83 Cr. (Mar 2025) to 24.43 Cr., marking an increase of 1.60 Cr..
However, the Borrowings (0.60 Cr.) are higher than the Reserves (0.42 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -7.79 | -7.43 | -6.97 | -6.92 | -0.04 | -0.19 | -1.92 | -7.33 | -5.56 | -9.43 | -2.60 | 2.95 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 116.56 | 126.81 | 123.81 | 114.31 | 57.62 | 53.29 | 68.16 | 74.94 | 49.75 | 62.34 | 43.11 | 36.86 |
| Inventory Days | 112.27 | 142.73 | 162.86 | 150.01 | 126.33 | 114.69 | 90.00 | 136.65 | 153.90 | 83.56 | 81.09 | 71.03 |
| Days Payable | 58.79 | 88.41 | 92.30 | 59.70 | 110.67 | 85.26 | 83.44 | 104.13 | 96.22 | 110.35 | 97.39 | 69.87 |
| Cash Conversion Cycle | 170.04 | 181.14 | 194.37 | 204.61 | 73.29 | 82.72 | 74.72 | 107.46 | 107.43 | 35.56 | 26.81 | 38.02 |
| Working Capital Days | 93.78 | 97.04 | 110.52 | 86.74 | 20.89 | 27.88 | 25.18 | -14.06 | 6.82 | -20.21 | -7.69 | -13.89 |
| ROCE % | 3.80% | 3.39% | 0.87% | 1.91% | 2.95% | 5.39% | 5.79% | -15.09% | 8.26% | -14.80% | 9.72% | 41.41% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -1.32 | 0.33 | -2.25 | 1.18 | -3.40 |
| Diluted EPS (Rs.) | -1.32 | 0.33 | -2.25 | 1.18 | -3.40 |
| Cash EPS (Rs.) | -0.80 | 0.82 | -1.76 | 1.55 | -3.16 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 8.73 | 9.58 | 9.25 | 11.50 | 10.32 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 8.73 | 9.58 | 9.25 | 11.50 | 10.32 |
| Revenue From Operations / Share (Rs.) | 67.64 | 64.65 | 63.05 | 54.09 | 33.93 |
| PBDIT / Share (Rs.) | 5.65 | 2.14 | -2.44 | 1.92 | -2.65 |
| PBIT / Share (Rs.) | 5.13 | 1.64 | -2.93 | 1.55 | -2.89 |
| PBT / Share (Rs.) | 4.57 | 0.73 | -3.90 | 1.01 | -3.41 |
| Net Profit / Share (Rs.) | -1.32 | 0.32 | -2.25 | 1.18 | -3.40 |
| PBDIT Margin (%) | 8.34 | 3.30 | -3.86 | 3.54 | -7.80 |
| PBIT Margin (%) | 7.58 | 2.54 | -4.64 | 2.85 | -8.50 |
| PBT Margin (%) | 6.75 | 1.13 | -6.18 | 1.86 | -10.05 |
| Net Profit Margin (%) | -1.94 | 0.50 | -3.57 | 2.17 | -10.00 |
| Return on Networth / Equity (%) | -15.10 | 3.42 | -24.35 | 10.22 | -32.89 |
| Return on Capital Employeed (%) | 37.36 | 10.95 | -18.22 | 8.09 | -21.08 |
| Return On Assets (%) | -4.28 | 1.04 | -5.85 | 3.18 | -11.55 |
| Long Term Debt / Equity (X) | 0.04 | 0.13 | 0.21 | 0.26 | 0.05 |
| Total Debt / Equity (X) | 0.14 | 0.54 | 1.06 | 0.78 | 0.59 |
| Asset Turnover Ratio (%) | 2.18 | 1.85 | 1.67 | 1.63 | 1.14 |
| Current Ratio (X) | 0.95 | 0.92 | 0.96 | 1.17 | 1.03 |
| Quick Ratio (X) | 0.66 | 0.59 | 0.69 | 0.68 | 0.70 |
| Inventory Turnover Ratio (X) | 13.10 | 1.80 | 1.11 | 1.40 | 0.95 |
| Interest Coverage Ratio (X) | 10.09 | 2.35 | -2.51 | 3.55 | -5.05 |
| Interest Coverage Ratio (Post Tax) (X) | -1.36 | 1.36 | -1.32 | 3.18 | -5.47 |
| Enterprise Value (Cr.) | 45.53 | 43.07 | 17.60 | 26.07 | 8.45 |
| EV / Net Operating Revenue (X) | 0.90 | 0.89 | 0.37 | 0.64 | 0.33 |
| EV / EBITDA (X) | 10.87 | 27.12 | -9.74 | 18.31 | -4.30 |
| MarketCap / Net Operating Revenue (X) | 0.90 | 0.81 | 0.26 | 0.48 | 0.20 |
| Price / BV (X) | 7.00 | 5.53 | 1.80 | 2.27 | 0.67 |
| Price / Net Operating Revenue (X) | 0.90 | 0.81 | 0.26 | 0.48 | 0.20 |
| EarningsYield | -0.02 | 0.01 | -0.13 | 0.04 | -0.48 |
After reviewing the key financial ratios for Gujarat Terce Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -1.32. This value is below the healthy minimum of 5. It has decreased from 0.33 (Mar 24) to -1.32, marking a decrease of 1.65.
- For Diluted EPS (Rs.), as of Mar 25, the value is -1.32. This value is below the healthy minimum of 5. It has decreased from 0.33 (Mar 24) to -1.32, marking a decrease of 1.65.
- For Cash EPS (Rs.), as of Mar 25, the value is -0.80. This value is below the healthy minimum of 3. It has decreased from 0.82 (Mar 24) to -0.80, marking a decrease of 1.62.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 8.73. It has decreased from 9.58 (Mar 24) to 8.73, marking a decrease of 0.85.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 8.73. It has decreased from 9.58 (Mar 24) to 8.73, marking a decrease of 0.85.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 67.64. It has increased from 64.65 (Mar 24) to 67.64, marking an increase of 2.99.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 5.65. This value is within the healthy range. It has increased from 2.14 (Mar 24) to 5.65, marking an increase of 3.51.
- For PBIT / Share (Rs.), as of Mar 25, the value is 5.13. This value is within the healthy range. It has increased from 1.64 (Mar 24) to 5.13, marking an increase of 3.49.
- For PBT / Share (Rs.), as of Mar 25, the value is 4.57. This value is within the healthy range. It has increased from 0.73 (Mar 24) to 4.57, marking an increase of 3.84.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -1.32. This value is below the healthy minimum of 2. It has decreased from 0.32 (Mar 24) to -1.32, marking a decrease of 1.64.
- For PBDIT Margin (%), as of Mar 25, the value is 8.34. This value is below the healthy minimum of 10. It has increased from 3.30 (Mar 24) to 8.34, marking an increase of 5.04.
- For PBIT Margin (%), as of Mar 25, the value is 7.58. This value is below the healthy minimum of 10. It has increased from 2.54 (Mar 24) to 7.58, marking an increase of 5.04.
- For PBT Margin (%), as of Mar 25, the value is 6.75. This value is below the healthy minimum of 10. It has increased from 1.13 (Mar 24) to 6.75, marking an increase of 5.62.
- For Net Profit Margin (%), as of Mar 25, the value is -1.94. This value is below the healthy minimum of 5. It has decreased from 0.50 (Mar 24) to -1.94, marking a decrease of 2.44.
- For Return on Networth / Equity (%), as of Mar 25, the value is -15.10. This value is below the healthy minimum of 15. It has decreased from 3.42 (Mar 24) to -15.10, marking a decrease of 18.52.
- For Return on Capital Employeed (%), as of Mar 25, the value is 37.36. This value is within the healthy range. It has increased from 10.95 (Mar 24) to 37.36, marking an increase of 26.41.
- For Return On Assets (%), as of Mar 25, the value is -4.28. This value is below the healthy minimum of 5. It has decreased from 1.04 (Mar 24) to -4.28, marking a decrease of 5.32.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 0.2. It has decreased from 0.13 (Mar 24) to 0.04, marking a decrease of 0.09.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.14. This value is within the healthy range. It has decreased from 0.54 (Mar 24) to 0.14, marking a decrease of 0.40.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 2.18. It has increased from 1.85 (Mar 24) to 2.18, marking an increase of 0.33.
- For Current Ratio (X), as of Mar 25, the value is 0.95. This value is below the healthy minimum of 1.5. It has increased from 0.92 (Mar 24) to 0.95, marking an increase of 0.03.
- For Quick Ratio (X), as of Mar 25, the value is 0.66. This value is below the healthy minimum of 1. It has increased from 0.59 (Mar 24) to 0.66, marking an increase of 0.07.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 13.10. This value exceeds the healthy maximum of 8. It has increased from 1.80 (Mar 24) to 13.10, marking an increase of 11.30.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 10.09. This value is within the healthy range. It has increased from 2.35 (Mar 24) to 10.09, marking an increase of 7.74.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -1.36. This value is below the healthy minimum of 3. It has decreased from 1.36 (Mar 24) to -1.36, marking a decrease of 2.72.
- For Enterprise Value (Cr.), as of Mar 25, the value is 45.53. It has increased from 43.07 (Mar 24) to 45.53, marking an increase of 2.46.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.90. This value is below the healthy minimum of 1. It has increased from 0.89 (Mar 24) to 0.90, marking an increase of 0.01.
- For EV / EBITDA (X), as of Mar 25, the value is 10.87. This value is within the healthy range. It has decreased from 27.12 (Mar 24) to 10.87, marking a decrease of 16.25.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.90. This value is below the healthy minimum of 1. It has increased from 0.81 (Mar 24) to 0.90, marking an increase of 0.09.
- For Price / BV (X), as of Mar 25, the value is 7.00. This value exceeds the healthy maximum of 3. It has increased from 5.53 (Mar 24) to 7.00, marking an increase of 1.47.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.90. This value is below the healthy minimum of 1. It has increased from 0.81 (Mar 24) to 0.90, marking an increase of 0.09.
- For EarningsYield, as of Mar 25, the value is -0.02. This value is below the healthy minimum of 5. It has decreased from 0.01 (Mar 24) to -0.02, marking a decrease of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Gujarat Terce Laboratories Ltd:
- Net Profit Margin: -1.94%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 37.36% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -15.1% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -1.36
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.66
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 54.4)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.14
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -1.94%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 122/2, Ravi Estate, Gandhinagar District Gujarat 382729 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Natwarbhai P Prajapati | Chairman |
| Mr. Amrutbhai P Prajapati | Whole Time Director |
| Mr. Aalap Prajapat | Managing Director & CEO |
| Mrs. Chhayaben A Shah | Independent Director |
| Mr. Viplav S Khamar | Independent Director |
| Mr. Surendra Kumar Sharma | Independent Director |
| Mr. Navinchandra Patel | Independent Director |
FAQ
What is the intrinsic value of Gujarat Terce Laboratories Ltd?
Gujarat Terce Laboratories Ltd's intrinsic value (as of 07 January 2026) is ₹18.94 which is 59.27% lower the current market price of ₹46.50, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹34.5 Cr. market cap, FY2025-2026 high/low of ₹87.8/37.2, reserves of ₹0.42 Cr, and liabilities of ₹24.43 Cr.
What is the Market Cap of Gujarat Terce Laboratories Ltd?
The Market Cap of Gujarat Terce Laboratories Ltd is 34.5 Cr..
What is the current Stock Price of Gujarat Terce Laboratories Ltd as on 07 January 2026?
The current stock price of Gujarat Terce Laboratories Ltd as on 07 January 2026 is ₹46.5.
What is the High / Low of Gujarat Terce Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Gujarat Terce Laboratories Ltd stocks is ₹87.8/37.2.
What is the Stock P/E of Gujarat Terce Laboratories Ltd?
The Stock P/E of Gujarat Terce Laboratories Ltd is .
What is the Book Value of Gujarat Terce Laboratories Ltd?
The Book Value of Gujarat Terce Laboratories Ltd is 10.6.
What is the Dividend Yield of Gujarat Terce Laboratories Ltd?
The Dividend Yield of Gujarat Terce Laboratories Ltd is 0.00 %.
What is the ROCE of Gujarat Terce Laboratories Ltd?
The ROCE of Gujarat Terce Laboratories Ltd is 41.4 %.
What is the ROE of Gujarat Terce Laboratories Ltd?
The ROE of Gujarat Terce Laboratories Ltd is 14.6 %.
What is the Face Value of Gujarat Terce Laboratories Ltd?
The Face Value of Gujarat Terce Laboratories Ltd is 10.0.